Antifungal Treatment for Onychomycosis with Minimal Gastric Side Effects

Systemic Antifungal Options

The British Journal of Dermatology recommends that all oral antifungals demonstrate comparable gastrointestinal tolerability, with gastrointestinal side effects occurring in approximately 49% of patients, including nausea, diarrhea, and taste disturbance 3
The British Journal of Dermatology suggests that terbinafine has superior efficacy to other agents, with 76-81% mycological cure rates, and recommends baseline liver function tests and complete blood count in patients with history of heavy alcohol consumption, hepatitis, or hematological abnormalities 1, 3
The British Journal of Dermatology states that itraconazole has common adverse effects, including headache and gastrointestinal upset, and recommends monitoring hepatic function tests, especially with concomitant hepatotoxic drugs 1, 2, 4
The British Journal of Dermatology notes that fluconazole has adverse effects, including headache and gastrointestinal upset, and may have fewer drug interactions than itraconazole 1, 2, 4
The British Journal of Dermatology recommends that griseofulvin has lower efficacy, with 30-40% mycological cure, and longer treatment duration required, and is no longer the treatment of choice unless other drugs are unavailable 1, 2, 3, 6, 7

The British Journal of Dermatology recommends that topical antifungals, such as amorolfine 5% lacquer, have rare adverse effects, including local burning, pruritus, and erythema, and are useful for superficial and distal onychomycosis 1, 2
The British Journal of Dermatology states that ciclopirox 8% lacquer has rare adverse effects, including periungual and nail fold erythema, and is indicated for patients in whom systemic therapy is contraindicated 1, 2

The British Journal of Dermatology suggests that for patients prioritizing gastric tolerability, mild to moderate distal/superficial disease should be treated with topical therapy to completely avoid systemic GI effects 1, 2
The British Journal of Dermatology recommends that severe or extensive disease requiring systemic therapy should be treated with terbinafine for superior efficacy, despite equivalent GI side effects 1, 3, 6

The British Journal of Dermatology notes that no oral antifungal is truly "benign" to the stomach, and all cause headache and GI upset as common side effects 1, 2, 4
The British Journal of Dermatology states that topical therapies are the only truly gastric-benign option, but have limited efficacy in severe disease 1, 2
The British Journal of Dermatology recommends that treatment should not commence before mycological confirmation of infection 7